Phosphorylated Epidermal Growth Factor Receptor Expression Is Associated With Clinicopathologic Parameters and Patient Survival in Mobile Tongue Squamous Cell Carcinoma
- 1 March 2017
- journal article
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 75 (3) , 632-640
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal CancerPLOS ONE, 2013
- pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinomaCancer Biology & Therapy, 2012
- FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survivalJournal of Cancer Research and Clinical Oncology, 2012
- Metallothionein expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patient survivalHistopathology, 2011
- EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinomaEuropean Journal of Cancer, 2009
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyThe Lancet Oncology, 2009
- Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinomaBritish Journal of Cancer, 2008
- Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomasBreast Cancer Research, 2008
- Metastasis of squamous cell carcinoma of the oral tongueCancer and Metastasis Reviews, 2007
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004